PROTEASOME INHIBITOR

Patent number:

EP24382811

Comunidad Valenciana.svg
No items found.

Researchers at the Universitat Jaume I and the Max Planck Institute have developed new proteasome inhibitors with pharmacological properties different from those developed until now.

Countries:
Spain
Regions:
Valencian Community
Centers:
UNIVERSITAT JAUME I
Other entities:
Max Planck Institute
Sectors:
Health
Subsectors:
TRL Level:
TRL 3 – experimental proof of concept
BRL Level:
PDF Link:
Download here
Video Link:
Watch it here
Sustainable Development Goal:
SDG03: Good health and well-being
Applications

- Compounds with higher affinity and more specific. - Improved properties with respect to commercial drugs (higher target selectivity and increased affinity).

Comments

The technology is the subject of a project to valorize research results.

Other related patents

Health
Chemicals

" Procedure for producing a regioisomeric mixture of two derivatives of (11R, 17R) -11-epi-fistularin-3, inhibitory mixture of human leukemia cells "

Countries
Spain
Know more
Health

New therapeutic target for the treatment of myotonic dystrophy

Countries
Spain
Know more
Health

PLATELET FUNCTIONALITY FOR EARLY DIAGNOSIS OF PARKINSON'S DISEASE

Countries
Spain
Know more
Get back to patents directory